Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23121688 | 0.86 | BRD4 (0.42) | BRD4BRD9MEN1KMT2AKDM4E | |
| SCHEMBL23123681 | 0.85 | BRD4 (0.42) | BRD4BRD9MEN1KMT2AKDM4E | |
| SCHEMBL23121650 | 0.81 | CYP3A4 (0.43) | BRD4BRD9MEN1KMT2AEGFR | |
| SCHEMBL23123058 | 0.79 | BRD4 (0.48) | BRD4BRD9MEN1KMT2AKDM4E | |
| SCHEMBL23121785 | 0.79 | BRD9 (0.52) | BRD9 | |
| SCHEMBL23121701 | 0.78 | BRD4 (0.41) | BRD4BRD9MEN1KMT2AKDM4E | |
| SCHEMBL30008965 | 0.78 | BRD4 (0.41) | BRD4BRD9MEN1KMT2AKDM4E | |
| SCHEMBL23134742 | 0.77 | DDB1 (0.44) | ALDH1A1EGFRHSD11B1 | |
| SCHEMBL23122817 | 0.77 | CYP3A4 (0.39) | BRD4BRD9KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23134075 | 0.76 | DDB1 (0.40) | MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-4041724-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | Novartis AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| CN-114641473-A | BRD9 bifunctional degradation agent and use method thereof | 诺华股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055295-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315578-A1 | BRD9 BIFUNCTIONAL DEGRADERS AND THEIR METHODS OF USE | BRD9, BRD2, BRD1 | BRD4 8/4885BRD9 1/4885MEN1 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.